サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1733384

眼科用医薬品と機器の世界市場規模：製品タイプ別、用途別、エンドユーザー別、地域範囲別および予測

Global Ophthalmology Drugs And Devices Market Size By Product Type (Anti-inflammatory, Anti-glaucoma), By Application (Dry Eye, Eye Allergy), By End-User (Hospitals, Medical Clinics), By Geographic Scope And Forecast

出版日
ページ情報
英文 202 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.76円
眼科用医薬品と機器の世界市場規模：製品タイプ別、用途別、エンドユーザー別、地域範囲別および予測
出版日: 2025年05月13日
発行: Verified Market Research
ページ情報: 英文 202 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

眼科用医薬品と機器の市場規模と予測

眼科用医薬品と機器の市場規模は、2024年に570億2,000万米ドルと評価され、2032年には881億8,000万米ドルに達すると予測され、2024～2032年のCAGRは5.60%で成長します。

眼科疾患や障害の有病率の増加、眼科疾患に対する人々の健康意識の高まり、強力な分子パイプラインの存在、眼科用医薬品と機器の採用増加などが、眼科用医薬品と機器の世界市場の成長を大きく促進しています。当レポートでは、眼科用医薬品と機器の世界市場について包括的な評価を行います。主要セグメント、動向、市場促進要因、抑制要因、競合情勢、市場で重要な役割を果たしている要因などを包括的に分析しています。

眼科用医薬品と機器の世界市場定義

眼科は、眼疾患の診断と治療に焦点を当てた医療セグメントです。眼科用機器は、白内障手術、緑内障手術、屈折矯正手術など、さまざまな手術に使用されます。眼科治療は、感染症、緑内障、白内障を含む幅広い眼疾患の治療に使用されます。黄斑変性症、老眼、糖尿病性網膜症など、眼に関連する疾患の罹患率や有病率が高齢者の間で上昇しているため、世界の眼科用医薬品と機器市場は大きな成長を遂げています。洗練された眼科機器の出現により、人々は眼に関連する障害を治療するために眼科手術を選択するようになってきています。

眼科用医薬品と機器の世界市場概要

眼科用医薬品と機器の世界市場は、高齢者の間で黄斑変性症、老眼、糖尿病性網膜症などの様々な眼関連疾患の治療における低侵襲手術の需要が増加しているため、今後数年間で著しい成長が見込まれます。眼疾患や障害の発生率や有病率の増加、眼疾患や障害に対する人々の健康意識の高まり、強力な分子パイプラインの存在、特定の眼奇形や眼欠損の治療や診断における眼科治療や機器の採用増加などが、世界の眼科治療・機器市場の成長を大きく促進しています。

さらに、眼科用医薬品と機器のセグメントにおける技術進歩や、新しい眼科用医薬品の開発のための研究開発活動への投資の増加も、市場の成長を促進しています。さらに、世界の高齢者の増加、高血糖による眼科疾患の増加、ヘルスケアセグメントの成長、診断機器や治療手順に対する資金や助成金といった形での政府の取り組みや支援の増加も、眼科用医薬品と機器市場の成長を後押ししています。

さらに、眼に関連する疾患の患者数の増加、製品開発・上市活動の活発化、眼内レンズや超音波乳化吸引機器の膨大な需要、新興国における成長の可能性などは、予測期間中、世界の眼科用医薬品と機器市場の市場関係者に有益な成長機会を提供すると期待されています。しかし、治療処置に伴う高額な費用、複数の医薬品がパイプラインにある中での医薬品承認の遅れ、眼科用医薬品の認知度の低さ、熟練した医療従事者の不足、特許切れなどが、予測期間中の眼科用医薬品と機器の世界市場の成長を妨げると予想されます。さらに、眼疾患治療に伴うリスクが眼科用医薬品と機器市場の成長に課題をもたらしています。

目次

第1章 世界の眼科用医薬品と機器市場の導入

  • 市場概要
  • 調査範囲
  • 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

  • データマイニング
  • バリデーション
  • 一次資料
  • データソース一覧

第4章 世界の眼科用医薬品と機器市場展望

  • 概要
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • ポーターのファイブフォースモデル
  • バリューチェーン分析

第5章 眼科用医薬品と機器の世界市場：製品タイプ別

  • 概要
  • 抗アレルギー剤
  • 抗血管内皮増殖因子（抗VEGF）薬
  • 抗炎症剤
  • 抗緑内障薬
  • 診断・モニタリング機器
  • 手術用機器
  • ビジョンケア
  • その他

第6章 眼科用医薬品と機器の世界市場：用途別

  • 概要
  • ドライアイ
  • 眼アレルギー
  • 緑内障
  • 白内障
  • 眼感染症
  • 網膜障害
  • ぶどう膜炎
  • その他

第7章 眼科用医薬品と機器の世界市場：エンドユーザー別

  • 概要
  • 病院
  • クリニック
  • 診断センター
  • その他

第8章 眼科用医薬品と機器の世界市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • その他の欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • その他のアジア太平洋
  • その他
    • 中東・アフリカ
    • ラテンアメリカ

第9章 世界の眼科用医薬品と機器市場の競合情勢

  • 概要
  • 各社の市場ランキング
  • 主要開発戦略

第10章 企業プロファイル

  • Carl Zeiss AG
  • Novartis AG
  • Johnson And Johnson Services, Inc.
  • Allergan
  • Topcon Corporation
  • Nidek Co., Ltd.
  • HAAG-STREIT GROUP
  • Ziemer Ophthalmic Systems
  • Bausch And Lomb Incorporated, BIoTech
  • VisionCare, Inc.
  • Akorn
  • Incorporated
  • Bayer AG
  • Acucela Inc.
  • Regeneron Pharmaceuticals, Inc
  • Nicox
  • Santen Pharmaceutical Co., Ltd
  • IRIDEX Corporation
  • Alcon Inc

第11章 企業プロファイル付録

    • 関連レポート
目次
Product Code: 69397

Ophthalmology Drugs And Devices Market Size And Forecast

Ophthalmology Drugs And Devices Market size was valued at USD 57.02 Billion in 2024 and is projected to reach USD 88.18 Billion by 2032, growing at a CAGR of 5.60% from 2024 to 2032.

The increasing prevalence of eye diseases and disorders, rising health awareness among people about the same, presence of a robust pipeline of molecules, and increase in adoption of ophthalmology drugs and devices are driving the growth of the Global Ophthalmology Drugs And Devices Market significantly. The Global Ophthalmology Drugs And Devices Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Ophthalmology Drugs And Devices Market Definition

Ophthalmology is a field of medical science that focuses on the diagnosis and treatment of eye disorders. Ophthalmic devices are used in a variety of procedures such as cataract surgery, glaucoma surgery, and refractive surgery. Ophthalmic drugs are used to treat a wide range of eye diseases, including infection, glaucoma, and cataract. The Global Ophthalmology Drugs And Devices Market is experiencing significant growth because of the rising incidence and prevalence of eye-related disorders such as macular degeneration, presbyopia, and diabetic retinopathy among the geriatric population. With the advent of sophisticated ophthalmic devices, people are increasingly going to opt for ophthalmic surgeries to cure their eye-related disorders.

Global Ophthalmology Drugs And Devices Market Overview

The Global Ophthalmology Drugs And Devices Market is expected to experience remarkable growth in the upcoming years owing to the increasing demand for minimally invasive surgeries in the treatment of various eye-related disorders such as macular degeneration, presbyopia, and diabetic retinopathy among the geriatric population. The increasing incidence and prevalence of eye diseases and disorders, rising health awareness among people about the same, presence of a robust pipeline of molecules, and increase in adoption of ophthalmology drugs and devices in the treatment and diagnosis of certain ocular malformations and eye deficits are fueling the growth of Global Ophthalmology Drugs And Devices Market significantly.

Additionally, technological advancement in the field of Ophthalmology Drugs and Devices and increasing investment in R&D activities for the development of new ophthalmological drugs are also promoting market growth. Furthermore, the rise in the geriatric population across the globe, increasing ophthalmic disorders due to high blood sugar, growth in the healthcare sector, and increasing government initiatives and support in the form of funds and grants for diagnostic equipment and treatment procedures, also boost the growth of the Ophthalmology Drugs And Devices Market.

Moreover, an increase in the patient population of eye-related disorders, increasing product development and launch activities, huge demand for intraocular lenses and phacoemulsification devices, and growth potential in developing nations are expected to provide profitable growth opportunities to the market players in the Global Ophthalmology Drugs And Devices Market during the forecast period. However, high cost associated with the treatment procedures, drug approval delays wherein multiple drugs are in the pipeline, low awareness of ophthalmic drugs, lack of skilled healthcare professionals, and patent expiry is expected to hinder the growth of the Global Ophthalmology Drugs And Devices Market over the forecast period. In addition, risks associated with ocular disease treatment are posing challenges to the growth of the Ophthalmology Drugs And Devices Market.

Global Ophthalmology Drugs And Devices Market Segmentation Analysis

The Global Ophthalmology Drugs And Devices Market is Segmented on the basis of Product Type, Application, End-User, and Geography.

Ophthalmology Drugs And Devices Market, By Product Type

  • Anti-allergy
  • Anti-Vascular Endothelial Growth Factor (Anti-VEGF) agents
  • Anti-inflammatory
  • Anti-glaucoma
  • Diagnostic and Monitoring Devices
  • Surgical Devices
  • Vision Care
  • Others

Based on Product Type, the market is bifurcated into Anti-allergy, Anti-Vascular Endothelial Growth Factor (Anti-VEGF) agents, Anti-inflammatory, Anti-glaucoma, Diagnostic and Monitoring Devices, Surgical Devices, Vision Care, and Others. The anti-inflammatory segment accounts for the highest revenue share of the Global market in 2020 and is expected to dominate the market over the forecast period owing to an increase in the prevalence of allergic conjunctivitis and hypersensitivity reactions, as well as an increase in demand for anti-inflammatory drugs in a wide range of conditions such as uveitis, cystoid macular edema, and scleritis. These factors are driving the growth of this segment.

Ophthalmology Drugs And Devices Market, By Application

  • Dry Eye
  • Eye Allergy
  • Glaucoma
  • Cataract
  • Eye Infection
  • Retinal Disorders
  • Uveitis
  • Others

Based on Application, the market is bifurcated into Dry Eye, Eye Allergy, Glaucoma, Cataract, Eye Infection, Retinal Disorders, Uveitis, and Others. The retinal disorders segment is expected to hold the largest revenue share of the global market during the forecast period owing to the rise in the geriatric population, increase in the prevalence of macular degeneration, and an increase in the sale of ophthalmic drugs for the treatment of retinal disorders. However, the glaucoma segment is expected to grow significantly during the forecast period due to an increase in glaucoma prevalence, a rising need for ophthalmic drugs, and an increase in glaucoma prevention and treatment awareness.

Ophthalmology Drugs And Devices Market, By End-User

  • Hospitals
  • Medical Clinics
  • Diagnostic Centers
  • Others

Based on End-User, the market is bifurcated into Hospitals, Medical Clinics, Diagnostic Centers, and Others. The hospitals segment is expected to grow at the highest CAGR during the forecast period owing to the increasing number of patients suffering from various eye-related disorders, and rising awareness about these disorders. Additionally, the availability of various diagnostics and treatment facilities, higher purchasing power, and the presence of highly skilled eye care professionals are driving the growth of the global market in the hospitals segment.

Ophthalmology Drugs And Devices Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World
  • On the basis of Regional Analysis, The Global Ophthalmology Drugs And Devices Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. Among the regional markets, North America accounts for the largest revenue share in the Global Ophthalmology Drugs And Devices Market in 2020 and is expected to retain its dominance throughout the forecast period. The revenue growth in the North American market is mainly attributed to the increased investment in R&D activities for the development of technologically advanced medical devices and innovative drugs for the treatment of various eye-related disorders.
  • Additionally, the increasing geriatric population, rising incidence and prevalence of various eye-related disorders, rising healthcare sectors, presence of skilled eye care professionals, and wide availability of technologically advanced ophthalmology devices are the major factors that boost the Ophthalmology Drugs And Devices Market growth across the region. The market in the Asia Pacific is projected to witness expansion at a significant growth rate during the forecast period, owing to the increasing focus on the development of healthcare infrastructure and the rising prevalence of various eye-related disorders such as glaucoma and cataract in developing nations such as China, and India in this region.

Key Players

The "Global Ophthalmology Drugs And Devices Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Carl Zeiss AG, Novartis AG, Johnson And Johnson Services, Inc., Allergan, Topcon Corporation, Nidek Co., Ltd., HAAG-STREIT GROUP, Ziemer Ophthalmic Systems, Bausch And Lomb Incorporated, Biotech, VisionCare, Inc., Akorn, Incorporated, Bayer AG, Acucela Inc., Regeneron Pharmaceuticals, Inc, Nicox, Santen Pharmaceutical Co., Ltd. and IRIDEX Corporation, Alcon Inc. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

  • In August 2020, Topcon Corporation purchased the Henson line of perimetry products, including the Henson 9000 and 7000, from the United Kingdom-based Elektron Eye Technology (EET) of Cambridge.
  • In January 2020, iCare's IC200 tonometer device was approved by the US FDA.
  • In March 2019, Alcon Inc. acquired Power Vision Inc., a privately held medical device development company based in the United States that specializes in fluid-based intraocular lens implants.
  • In August 2018, CEQUA, developed by Sun Pharmaceutical Industries Ltd., had been approved by the US FDA for the treatment of dry eye diseases.
  • In July 2018, Amring Pharmaceuticals, Inc. introduced Biolon ophthalmic viscosurgical devices for cataract surgeons in the United States.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL OPHTHALMOLOGY DRUGS AND DEVICES MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL OPHTHALMOLOGY DRUGS AND DEVICES MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL OPHTHALMOLOGY DRUGS AND DEVICES MARKET, BY PRODUCT TYPE

  • 5.1 Overview
  • 5.2 Anti-allergy
  • 5.3 Anti-Vascular Endothelial Growth Factor (Anti-VEGF) agents
  • 5.4 Anti-inflammatory
  • 5.5 Anti-glaucoma
  • 5.6 Diagnostic and Monitoring Devices
  • 5.7 Surgical Devices
  • 5.8 Vision Care
  • 5.9 Others

6 GLOBAL OPHTHALMOLOGY DRUGS AND DEVICES MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Dry Eye
  • 6.3 Eye Allergy
  • 6.4 Glaucoma
  • 6.5 Cataract
  • 6.6 Eye Infection
  • 6.7 Retinal Disorders
  • 6.8 Uveitis
  • 6.9 Others

7 GLOBAL OPHTHALMOLOGY DRUGS AND DEVICES MARKET, BY END-USER

  • 7.1 Overview
  • 7.2 Hospitals
  • 7.3 Medical Clinics
  • 7.4 Diagnostic Centers
  • 7.5 Others

8 GLOBAL OPHTHALMOLOGY DRUGS AND DEVICES MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Middle East and Africa
    • 8.5.2 Latin America

9 GLOBAL OPHTHALMOLOGY DRUGS AND DEVICES MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Carl Zeiss AG
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Novartis AG
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Johnson And Johnson Services, Inc.
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Allergan
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Topcon Corporation
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Nidek Co., Ltd.
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 HAAG-STREIT GROUP
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Ziemer Ophthalmic Systems
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Bausch And Lomb Incorporated, Biotech
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 9.10 VisionCare, Inc.
    • 9.10.1 Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Outlook
    • 9.10.4 Key Developments
  • 9.11 Akorn
    • 9.11.1 Overview
    • 9.11.2 Financial Performance
    • 9.11.3 Product Outlook
    • 9.11.4 Key Developments
  • 9.12 Incorporated
    • 9.12.1 Overview
    • 9.12.2 Financial Performance
    • 9.12.3 Product Outlook
    • 9.12.4 Key Developments
  • 9.13 Bayer AG
    • 9.13.1 Overview
    • 9.13.2 Financial Performance
    • 9.13.3 Product Outlook
    • 9.13.4 Key Developments
  • 9.14 Acucela Inc.
    • 9.14.1 Overview
    • 9.14.2 Financial Performance
    • 9.14.3 Product Outlook
    • 9.14.4 Key Developments
  • 9.15 Regeneron Pharmaceuticals, Inc
    • 9.15.1 Overview
    • 9.15.2 Financial Performance
    • 9.15.3 Product Outlook
    • 9.15.4 Key Developments
  • 9.16 Nicox
    • 9.16.1 Overview
    • 9.16.2 Financial Performance
    • 9.16.3 Product Outlook
    • 9.16.4 Key Developments
  • 9.17 Santen Pharmaceutical Co., Ltd
    • 9.17.1 Overview
    • 9.17.2 Financial Performance
    • 9.17.3 Product Outlook
    • 9.17.4 Key Developments
  • 9.18 IRIDEX Corporation
    • 9.18.1 Overview
    • 9.18.2 Financial Performance
    • 9.18.3 Product Outlook
    • 9.18.4 Key Developments
  • 9.19 Alcon Inc
    • 9.19.1 Overview
    • 9.19.2 Financial Performance
    • 9.19.3 Product Outlook
    • 9.19.4 Key Developments

11 Appendix

    • 11.1.1 Related Reports